OBJECTIVE: This study was designed to establish estimates of the smallest effects due to chemopreventive intervention detectable by karyometry in skin biopsies. METHODS: Estimates of the smallest change of statistical significance and estimates of the power of the test were derived for several key features descriptive of the distribution of nuclear chromatin. Results from triplicate biopsies from the same case were used to provide estimates of the within-case, biopsy-to-biopsy variance. RESULTS: Generally, a change in feature value due to chemopreventive intervention can be statistically secured when it amounts to 5% to 10%. In clinical trials where matched baseline and end of study biopsies from the same cases are available, paired comparison ANOVA can detect a 2% change on samples of 25 cases. Establishing efficacy in individual cases requires a change in feature values on the order of 10% to 15%. CONCLUSIONS: Karyometry provides a sensitive, quantitative method for the assessment of efficacy of chemoprevention. The effects of within-case, biopsy-to-biopsy variance need to be considered only in the evaluation of individual cases and are on the order of 5% in skin biopsies.
OBJECTIVE: This study was designed to establish estimates of the smallest effects due to chemopreventive intervention detectable by karyometry in skin biopsies. METHODS: Estimates of the smallest change of statistical significance and estimates of the power of the test were derived for several key features descriptive of the distribution of nuclear chromatin. Results from triplicate biopsies from the same case were used to provide estimates of the within-case, biopsy-to-biopsy variance. RESULTS: Generally, a change in feature value due to chemopreventive intervention can be statistically secured when it amounts to 5% to 10%. In clinical trials where matched baseline and end of study biopsies from the same cases are available, paired comparison ANOVA can detect a 2% change on samples of 25 cases. Establishing efficacy in individual cases requires a change in feature values on the order of 10% to 15%. CONCLUSIONS: Karyometry provides a sensitive, quantitative method for the assessment of efficacy of chemoprevention. The effects of within-case, biopsy-to-biopsy variance need to be considered only in the evaluation of individual cases and are on the order of 5% in skin biopsies.
Authors: Peter H Bartels; James Ranger-Moore; M Suzanne Stratton; Paul Bozzo; Janine Einspahr; Yun Liu; Deborah Thompson; David S Alberts Journal: Anal Quant Cytol Histol Date: 2002-08 Impact factor: 0.302
Authors: J Ranger-Moore; D S Alberts; R Montironi; F Garcia; J Davis; D Frank; M Brewer; G M Mariuzzi; H G Bartels; P H Bartels Journal: Eur J Cancer Date: 2005-09 Impact factor: 9.162
Authors: Peter H Bartels; Carol J Fabian; Bruce F Kimler; James R Ranger-Moore; Denise H Frank; Michael L Yozwiak; David S Alberts Journal: Anal Quant Cytol Histol Date: 2007-04 Impact factor: 0.302
Authors: P Bozzo; D S Alberts; L Vaught; V D da Silva; D Thompson; J Warnecke; R C Miller; J Einspahr; P H Bartels Journal: Anal Quant Cytol Histol Date: 2001-08 Impact factor: 0.302
Authors: James Ranger-Moore; Paul Bozzo; David Alberts; Janine Einspahr; Yun Liu; Deborah Thompson; Steven Stratton; M Suzanne Stratton; Peter Bartels Journal: Anal Quant Cytol Histol Date: 2003-12 Impact factor: 0.302
Authors: Peter H Bartels; Robert S Krouse; Anil R Prasad; Michael Yozwiak; Yun Liu; Hubert G Bartels; David S Alberts Journal: Anal Quant Cytol Histol Date: 2008-12 Impact factor: 0.302
Authors: Steven P Stratton; David S Alberts; Janine G Einspahr; Paul M Sagerman; James A Warneke; Clara Curiel-Lewandrowski; Paul B Myrdal; Kelly L Karlage; Brian J Nickoloff; Chris Brooks; Kathylynn Saboda; Michael L Yozwiak; Mary F Krutzsch; Chengcheng Hu; Maria Lluria-Prevatt; Zigang Dong; G Timothy Bowden; Peter H Bartels Journal: Cancer Prev Res (Phila) Date: 2010-01-26